Abbott Laboratories Pakistan Ltd

The company maintains a strong liquidity position, with a current ratio of 1.65, indicating sufficient short-term assets to cover liabilities. Free cash flow stands at 498.99 million PKR, supporting operational flexibility and potential reinvestment. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity risk. Profitability metrics show a return on equity (ROE) of 3.03% and a return on assets (ROA) of 1.74%, both below the typical thresholds for high-performing pharmaceutical firms. The operating margin of 8.25% (calculated from operating income of 1.33 billion PKR on revenue of 16.17 billion PKR) is in line with industry norms but leaves room for improvement in cost efficiency. Geographically, the company is concentrated in Pakistan, with all disclosed revenue generated domestically. Segment-wise, the business is not publicly segmented into distinct product lines, but the primary revenue driver is pharmaceuticals, including branded and generic drugs. This lack of diversification increases exposure to local economic and regulatory shifts. Looking ahead, the company is expected to maintain stable revenue, with no significant growth or contraction projected in the next fiscal year. Capital expenditure of -1.04 billion PKR suggests a reduction in investment, potentially signaling a focus on cost control or asset optimization. Risk factors include medium liquidity risk due to the negative net cash position and low dilution risk, as shares outstanding remain unchanged between basic and diluted measures. No recent dilutive events are reported, and the debt-to-equity ratio is effectively zero, indicating a conservative capital structure. Recent filings and transcripts are not available in the provided data, but the company’s 10-K Risk Factors language and capital structure suggest no immediate pressure for equity issuance. The absence of ATM or shelf registration disclosures further supports the low dilution risk assessment.